JPWO2022073138A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022073138A5 JPWO2022073138A5 JP2023521536A JP2023521536A JPWO2022073138A5 JP WO2022073138 A5 JPWO2022073138 A5 JP WO2022073138A5 JP 2023521536 A JP2023521536 A JP 2023521536A JP 2023521536 A JP2023521536 A JP 2023521536A JP WO2022073138 A5 JPWO2022073138 A5 JP WO2022073138A5
- Authority
- JP
- Japan
- Prior art keywords
- nanocage
- monomer
- cov
- sars
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims description 107
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 107
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 107
- 239000002091 nanocage Substances 0.000 claims description 95
- 239000000178 monomer Substances 0.000 claims description 87
- 102000037865 fusion proteins Human genes 0.000 claims description 66
- 108020001507 fusion proteins Proteins 0.000 claims description 66
- 230000004927 fusion Effects 0.000 claims description 54
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 49
- 238000008416 Ferritin Methods 0.000 claims description 48
- 241001678559 COVID-19 virus Species 0.000 claims description 46
- 102000008857 Ferritin Human genes 0.000 claims description 42
- 108050000784 Ferritin Proteins 0.000 claims description 42
- 239000012634 fragment Substances 0.000 claims description 26
- 108010002084 Apoferritins Proteins 0.000 claims description 22
- 102000000546 Apoferritins Human genes 0.000 claims description 22
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 12
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 12
- 230000035772 mutation Effects 0.000 claims description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 108010068996 6,7-dimethyl-8-ribityllumazine synthase Proteins 0.000 claims description 4
- 101710132601 Capsid protein Proteins 0.000 claims description 4
- 108010058432 Chaperonin 60 Proteins 0.000 claims description 4
- 102000006303 Chaperonin 60 Human genes 0.000 claims description 4
- 101710094648 Coat protein Proteins 0.000 claims description 4
- 101710088194 Dehydrogenase Proteins 0.000 claims description 4
- -1 E2P Proteins 0.000 claims description 4
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims description 4
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 4
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 4
- 101710125418 Major capsid protein Proteins 0.000 claims description 4
- 101710141454 Nucleoprotein Proteins 0.000 claims description 4
- 101710083689 Probable capsid protein Proteins 0.000 claims description 4
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 108091005774 SARS-CoV-2 proteins Proteins 0.000 claims description 3
- 125000000539 amino acid group Chemical group 0.000 claims description 3
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 description 6
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 5
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 5
- 101000818390 Homo sapiens Ferritin light chain Proteins 0.000 description 3
- 108091006047 fluorescent proteins Proteins 0.000 description 2
- 102000034287 fluorescent proteins Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- RQVYBGPQFYCBGX-UHFFFAOYSA-N ametryn Chemical compound CCNC1=NC(NC(C)C)=NC(SC)=N1 RQVYBGPQFYCBGX-UHFFFAOYSA-N 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089782P | 2020-10-09 | 2020-10-09 | |
| US63/089,782 | 2020-10-09 | ||
| US202163197236P | 2021-06-04 | 2021-06-04 | |
| US63/197,236 | 2021-06-04 | ||
| US202163220929P | 2021-07-12 | 2021-07-12 | |
| US63/220,929 | 2021-07-12 | ||
| PCT/CA2021/051426 WO2022073138A1 (en) | 2020-10-09 | 2021-10-08 | Polypeptides targeting sars-cov-2 and related compositions and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023544211A JP2023544211A (ja) | 2023-10-20 |
| JPWO2022073138A5 true JPWO2022073138A5 (enExample) | 2024-10-17 |
Family
ID=81126329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023521536A Pending JP2023544211A (ja) | 2020-10-09 | 2021-10-08 | Ｓａｒｓ－ｃｏｖ－２を標的とするポリペプチドならびに関連する組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250263469A1 (enExample) |
| EP (1) | EP4225804A4 (enExample) |
| JP (1) | JP2023544211A (enExample) |
| KR (1) | KR20230083316A (enExample) |
| AU (1) | AU2021356355A1 (enExample) |
| BR (1) | BR112023006497A2 (enExample) |
| CA (1) | CA3197642A1 (enExample) |
| MX (1) | MX2023004023A (enExample) |
| WO (1) | WO2022073138A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240317842A1 (en) * | 2021-01-28 | 2024-09-26 | The Hospital For Sick Children | Multabody constructs, compositions, and methods |
| MX2024000662A (es) * | 2021-07-12 | 2024-05-06 | Hospital For Sick Children | Construcciones, composiciones y métodos de anticuerpos multiespecíficos optimizados. |
| KR20240058026A (ko) * | 2022-10-21 | 2024-05-03 | 충남대학교산학협력단 | SARS-CoV-2 S1 유래 단백질 및 항체 Fc 영역 단백질을 표면에 동시에 디스플레이하는 페리틴 단백질 구조체 및 이의 코로나바이러스 SARS-CoV-2에 대한 백신 용도 |
| EP4605437A1 (en) * | 2022-10-21 | 2025-08-27 | The Hospital For Sick Children | Multabody constructs, compositions, and methods targeting sarbecoviruses |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011056997A1 (en) * | 2009-11-04 | 2011-05-12 | Fabrus Llc | Methods for affinity maturation-based antibody optimization |
| BR112015002091A2 (pt) * | 2012-08-02 | 2017-12-12 | Hoffmann La Roche | método para a produção de um polipeptídeo, polipeptídeo, uso de um polipeptídeo e composição |
| WO2015109212A1 (en) * | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
| HUE045466T2 (hu) * | 2014-11-06 | 2019-12-30 | Hoffmann La Roche | Fc-régió-variánsok módosított FcRn-kötéssel és alkalmazási eljárások |
| WO2017196847A1 (en) * | 2016-05-10 | 2017-11-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens |
| RU2019104896A (ru) * | 2016-07-22 | 2020-08-24 | Дана-Фарбер Кэнсер Инститьют, Инк. | Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и способы их использования |
| EP3661968B1 (en) * | 2017-08-04 | 2022-03-02 | The Hospital for Sick Children | Nanoparticle platform for antibody and vaccine delivery |
| CR20220552A (es) * | 2020-04-02 | 2023-01-17 | Regeneron Pharma | Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno |
| CN111592595B (zh) * | 2020-04-27 | 2021-02-19 | 南京医科大学 | 抗新型冠状病毒SARS-Cov-2的中和性抗体及其应用 |
-
2021
- 2021-10-08 KR KR1020237015177A patent/KR20230083316A/ko active Pending
- 2021-10-08 MX MX2023004023A patent/MX2023004023A/es unknown
- 2021-10-08 CA CA3197642A patent/CA3197642A1/en active Pending
- 2021-10-08 EP EP21876827.3A patent/EP4225804A4/en active Pending
- 2021-10-08 US US18/030,944 patent/US20250263469A1/en active Pending
- 2021-10-08 WO PCT/CA2021/051426 patent/WO2022073138A1/en not_active Ceased
- 2021-10-08 JP JP2023521536A patent/JP2023544211A/ja active Pending
- 2021-10-08 AU AU2021356355A patent/AU2021356355A1/en active Pending
- 2021-10-08 BR BR112023006497A patent/BR112023006497A2/pt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7337204B2 (ja) | 単鎖可変フラグメントｃｄ３結合タンパク質 | |
| JP2020517287A5 (enExample) | ||
| JP4011914B2 (ja) | キメラポリペプチド、その製造方法、およびその使用 | |
| US20170210818A1 (en) | Constant region antibody fusion proteins and compositions thereof | |
| JP2001521496A (ja) | 高い結合活性の多価および多特異的試薬 | |
| JP2018515085A5 (enExample) | ||
| IL285101B2 (en) | Antibodies targeting g-protein coupled receptor and methods of use | |
| CN109071654A (zh) | 靶向Fc受体样5的抗体及使用方法 | |
| JP2018502050A5 (enExample) | ||
| JP2020500885A5 (enExample) | ||
| JP2020505919A5 (enExample) | ||
| WO2023186120A1 (zh) | 抗血清白蛋白纳米抗体及其衍生物 | |
| JP2024504777A (ja) | Ｍｕｌｔａｂｏｄｙ構築物、組成物および方法 | |
| JP2019505565A5 (enExample) | ||
| CN115461354A (zh) | 用于分子缀合或改造的串联重复癌症靶向肽及其在癌症治疗诊断学中的用途 | |
| JPWO2020014132A5 (enExample) | ||
| JPWO2021116182A5 (enExample) | ||
| JPWO2022073138A5 (enExample) | ||
| JPWO2021139758A5 (enExample) | ||
| JP2023550191A (ja) | Ｄｒ４および／またはｄｒ５を標的とするポリペプチドならびに関連する組成物および方法 | |
| JP2023548345A (ja) | クリッピング率の低減した抗原結合ドメイン | |
| JPWO2022160057A5 (enExample) | ||
| JPWO2022129560A5 (enExample) | ||
| JPWO2023186120A5 (enExample) | ||
| JPWO2022104236A5 (enExample) |